| human | Q5 |
| P735 | given name | Jeffrey | Q13028078 |
| Jeffrey | Q13028078 | ||
| P106 | occupation | researcher | Q1650915 |
| Q46909059 | A CD4/Foxp3/OX40 triple immunofluorescence assay determines association between T cell immune subsets and outcome in colorectal cancer |
| Q38867604 | A distinct role for Lgr5+ stem cells in primary and metastatic colon cancer |
| Q28730141 | Active PI3K pathway causes an invasive phenotype which can be reversed or promoted by blocking the pathway at divergent nodes |
| Q52351955 | Airway pathological heterogeneity in asthma: Visualization of disease microclusters using topological data analysis. |
| Q42572857 | Anti-EGFL7 antibodies enhance stress-induced endothelial cell death and anti-VEGF efficacy |
| Q46659724 | Anti-VEGF antibody therapy does not promote metastasis in genetically engineered mouse tumour models |
| Q36034499 | B-cell activation influences T-cell polarization and outcome of anti-CD20 B-cell depletion in central nervous system autoimmunity |
| Q46097041 | Blocking vascular endothelial growth factor-A inhibits the growth of pituitary adenomas and lowers serum prolactin level in a mouse model of multiple endocrine neoplasia type 1. |
| Q48270031 | CD8+ T cell infiltration in breast and colon cancer: A histologic and statistical analysis |
| Q43768359 | CRIg mediates early Kupffer cell responses to adenovirus |
| Q42370777 | Combined MEK and ERK inhibition overcomes therapy-mediated pathway reactivation in RAS mutant tumors |
| Q27349020 | Combined targeting of BRAF and CRAF or BRAF and PI3K effector pathways is required for efficacy in NRAS mutant tumors |
| Q48510892 | Correction: Combined MEK and ERK inhibition overcomes therapy-mediated pathway reactivation in RAS mutant tumors |
| Q36673264 | DLK initiates a transcriptional program that couples apoptotic and regenerative responses to axonal injury. |
| Q39761203 | Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival |
| Q27322781 | EGFR inhibitor erlotinib delays disease progression but does not extend survival in the SOD1 mouse model of ALS |
| Q44193323 | Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial |
| Q28741802 | FGF19 regulates cell proliferation, glucose and bile acid metabolism via FGFR4-dependent and independent pathways |
| Q45894130 | Heterogeneity of cytotoxic T cell infiltration in breast and colorectal cancer |
| Q36569352 | IL-33 amplifies an innate immune response in the degenerating retina. |
| Q35485785 | Impaired FcεRI stability, signaling, and effector functions in murine mast cells lacking glycosylphosphatidylinositol-anchored proteins |
| Q29620506 | Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis |
| Q36061581 | MHC class II distribution in dendritic cells and B cells is determined by ubiquitin chain length |
| Q37382526 | Mapping in vivo tumor oxygenation within viable tumor by 19F-MRI and multispectral analysis |
| Q42264735 | Monitoring and Targeting Anti-VEGF Induced Hypoxia within the Viable Tumor by 19F-MRI and Multispectral Analysis |
| Q28384680 | Multimodal microvascular imaging reveals that selective inhibition of class I PI3K is sufficient to induce an antivascular response |
| Q41965864 | Negative regulation of autoimmune demyelination by the inhibitory receptor CLM-1. |
| Q24322629 | PPM1H is a p27 phosphatase implicated in trastuzumab resistance |
| Q39718360 | PlGF blockade does not inhibit angiogenesis during primary tumor growth |
| Q34463435 | Residual tumor cells that drive disease relapse after chemotherapy do not have enhanced tumor initiating capacity |
| Q38311813 | Specification of type 2 innate lymphocytes by the transcriptional determinant Gfi1. |
| Q39840667 | Suppression of HER2/HER3-mediated growth of breast cancer cells with combinations of GDC-0941 PI3K inhibitor, trastuzumab, and pertuzumab |
| Q38818525 | Targeting LGR5+ cells with an antibody-drug conjugate for the treatment of colon cancer |
| Q33569337 | Transcription factor Etv5 is essential for the maintenance of alveolar type II cells |
| Q57465824 | Ubiquitin ligase COP1 coordinates transcriptional programs that control cell type specification in the developing mouse brain |
Search more.